Pfizer has played a critical role in healthcare for more than a century and now is helping to usher in a new era of vaccine development. As a global leader in pneumococcal disease prevention, Pfizer will continue to push the boundaries of innovation. Not only has Pfizer developed Trumenba, to prevent meningococcal group B disease, they are currently working on a vaccine for Staphylococcus aureus, the leading cause of hospital-acquired infections.
Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) is a vaccine approved for children 6 weeks through adults for the prevention of pneumococcal pneumonia and invasive disease caused by 13 Streptococcus pneumoniae strains (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). See full prescribing information for specific indications and more.
TRUMENBA® (Meningococcal Group B Vaccine), is the first FDA-approved vaccine for active immunization to prevent invasive disease caused by Neisseria meningitidis group B. It is indicated for individuals 10 through 25 years of age. To learn more about Trumenba please visit here.
If you do not have a direct account with Pfizer, you may download the form here – Pfizer Direct Account form. MPPG will need your new account number once one is provided to you from Pfizer.
Let Pfizer help you reach your patients with their Vaccine Adherence in Kids (VAKs) program.
MPPG members currently receive an incredible 19% discount on Trumenba® (Meningococcal Group B Vaccine) when ordered directly from Pfizer vaccines, https://primevaccines.pfizer.com .
TRUMENBA® is a registered trademark of Wyeth LLC.
PFIZER® is a registered trademark of Pfizer Inc.